Back
Urea cycle disorders-update.
Journal article

Urea cycle disorders-update.

  • Matsumoto S Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. s-pediat@gpo.kumamoto-u.ac.jp.
  • Häberle J University Children's Hospital Zurich and Children's Research Centre, Zurich, 8032, Switzerland.
  • Kido J Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Mitsubuchi H Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Endo F Kumamoto Ezuko Institution for Developmental Disabilities, Kumamoto, Japan.
  • Nakamura K Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Show more…
  • 2019-05-22
Published in:
  • Journal of human genetics. - 2019
Arginase
Brain
Carbamoyl-Phosphate Synthase (Ammonia)
Humans
Mutation
Ornithine Carbamoyltransferase
Urea Cycle Disorders, Inborn
English The urea cycle is a metabolic pathway for the disposal of excess nitrogen, which arises primarily as ammonia. Nitrogen is essential for growth and life-maintenance, but excessive ammonia leads to life-threatening conditions. The urea cycle disorders (UCDs) comprise diseases presenting with hyperammonemia that arise in either the neonatal period (about 50% of cases) or later. Congenital defects of the enzymes or transporters of the urea cycle cause the disease. This cycle utilizes five enzymes, two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix, whereas the others (argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm. In addition, N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function. Severity and age of onset depend on residual enzyme or transporter function and are related to the respective gene mutations. The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain. The pathogenesis and natural course are poorly understood because of the rarity of the disease, so an international registry system and novel clinical trials are much needed. We review here the current concepts of the pathogenesis, diagnostics, including genetics and treatment of UCDs.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/30353
Statistics
Document views: 93 File downloads: